AltOligo: Alternative chemistry for oligonucleotide synthesis using Nanostar Sieving

AltOligo：使用 Nanostar 筛分合成寡核苷酸的替代化学方法

• 批准号: 10062368
• 金额: $ 274.1万
• 依托单位: EXACTMER LIMITED
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10062368
• 关键词: AltOligo; Alternative; chemistry; oligonucleotide; synthesis

Millions of molecules are made of repeating units of individual building blocks (monomers). DNA and RNA are important natural polymers made of repeating nucleotides as building blocks. The manufacture of short strands of chemically modified RNA (oligonucleotides) has shown great promise for the development of novel therapies. It is currently achieved using solid-phase synthesis in which the growing oligo is bound to an insoluble substrate and monomers are added one at a time. Solid-phase synthesis is difficult to scale and the resulting purity is low, leading to high prices. The UK start-up Exactmer has developed patented technology enabling polymer synthesis entirely in the liquid phase to overcome these obstacles. The EU-funded NANOLIGO project will bring this technology to market with the potential to significantly speed the development of novel complex polymeric pharmaceuticals and slash manufacturing costs.

数以百万计的分子是由单个构件(单体)的重复单元组成的。DNA和RNA是由重复核苷酸组成的重要天然聚合物。化学修饰的短链RNA(寡核苷酸)的制造为开发新的治疗方法展示了巨大的前景。目前，它是通过固相合成法实现的，在固相合成法中，生长的低聚物结合到不溶于水的底物上，并一次添加一个单体。固相合成法难以规模化，所得产品纯度低，导致价格高昂。英国初创企业Exactmer开发了一项专利技术，能够完全在液体中合成聚合物，以克服这些障碍。欧盟资助的NANOLIGO项目将把这项技术推向市场，有可能显著加快新型复杂聚合物药物的开发，并大幅削减制造成本。